

Digestive System Loss of Appetite

patients receiving dextro

*Included doses up to 40 mg.

Dose-related adverse reactions

Body System

Digestive System

rvous System

Metabolic/Nutritional Weight Loss

lability, libido decreased, somnol

doses [see Warnings and Precautions (5.2)].

Eve Disorders: Vision blurred, mydriasis.

Vascular Disorders: Raynaud's phenomenon

Monoamine Oxidase Inhibitors (MAOIs)

Skin: Alopecia.

7 DRUG INTERACTIONS

Serotonergic Drugs

ervention

nical Im

*Included doses up to 60 mg.

Hypertension

Appears the same due to rounding

Urinary Tract Infection

dyspnea, sweating, dysmenorrhea, and impotence.

Cardiovascular

System

General

Appears the same due to rounding

Nervousness

Weight Lossb

Preferred Term

Headache

Asthenia

Dry Mouth

lausea

Agitation

Anxiety

Dizziness Nervousness

Tachycardia

Diarrhea

Loss of Appetite

vous System

Nutritional

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE EXTENDED-RELEASE CAPSULES safely and effectively. See full prescribing information for DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE EXTENDED-RELEASE CAPSULES.

DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE extended-release capsules (mixed salts of a single-entity amphetamine product), for oral use, Cl

Initial U.S. Approval: 2001

WARNING: ABUSE, MISUSE, AND ADDICTION

See full prescribing information for complete boxed warning. Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules can reput in guerdees and death (51, 92, 10): capsules, can result in overdose and death (5.1, 9.2, 10):

- Before prescribing dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules, assess each patient's risk for abuse, misuse, and addiction.
- Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug.

Throughout treatment, reassess each patient's risk and frequently monitor for signs and symptoms of abuse misuse and addiction

	4
RECENT MAJOR CHANGES	
Boxed Warning 10/2023	į.

Boxed Warning Indications and Usage (1) Dosage and Administration (2.1, 2.2, 2.7)

Contraindications (4)

Warnings and Precautions (5.1, 5.2, 5.3, 5.4, 5.5, 5.7, 5.9) -----INDICATIONS AND USAGE--

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules, a CNS stimulant, are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older. (1)

----DOSAGE AND ADMINISTRATION-Pediatric patients (ages 6 to 17): 10 mg once daily in the morning. Maximum dose for children 6 to 12 years of age is 30 mg once daily. (2.2, 2.3, 2.4)

Adults: 20 mg once daily in the morning. (2.5)

Pediatric patients (ages 6 to 17) with severe renal impairment: 5 mg once daily in the morning. Maximum dose for children 6 to 12 years of age with severe renal impairment is 20 mg once daily. (2.6, 8.6)

• Adults with severe renal impairment: 15 mg once daily in the morning. (2.6, 8.6) Patients with ESRD: Not recommended. (2.6, 8.6)

-----DOSAGE FORMS AND STRENGTHS

Extended-release capsules: 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg (3)

----CONTRAINDICATIONS

Known hypersensitivity or idiosyncrasy to amphetamine (4)

FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: ABUSE, MISUSE, AND ADDICTION

1 INDICATIONS AND USAGE

1.1 Attention Deficit Hyperactivity Disorder 2 DOSAGE AND ADMINISTRATION

2.1 Pretreatment Screening

- 2.2 General Administration Information
- 2.3 Recommended Dosage in Pediatric Patients 6 to 12 Years

2.4 Recommended Dosage in Pediatric Patients 13 to 17 Years 2.5 Recommended Dosage in Adults

- 2.6 Dosage in Patients with Renal Impairment
- 2.7 Dosage Modification Due to Drug Interactions

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS 5.1 Abuse, Misuse, and Addiction

- 5.2 Risks to Patients with Serious Cardiac Disease
- 5.3 Increased Blood Pressure and Heart Rate 5.4 Psychiatric Adverse Reactions
- 5.5 Long-Term Suppression of Growth in Pediatric Patients
- 5.6 Seizures 5.7 Peripheral Vasculopathy, Including Raynaud's Phenomenon

5.8 Serotonin Syndrome

5.9 Motor and Verbal Tics, and Worsening of Tourette's Syndrome

6 ADVERSE REACTIONS 6.1 Clinical Trials Experience

6.2 Adverse Reactions Associated with the Use of Amphetamine, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended-Release Capsules, or Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate Tablets

FULL PRESCRIBING INFORMATION

WARNING: ABUSE, MISUSE, AND ADDICTION

phetamine saccharate, amphetamine aspartate monohydrate, dextroampheta suffate, ampletamine suffate extended-release capsules has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules, can result in overdose and death *[see Overdosage (10)]*, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.

Before prescribing dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules, assess each patient's risk for abuse, misuse, and addiction. Educate patients and their families about patients' risk for abuse, misuse, and aduction. Educate patients and their rainmise about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules treatment, reasses each patient's risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction *[see Warnings and Precautions (5.1), Drug Abuse and Dependence (9.2)]*.

During or within 14 days following the administration of monoamine oxidase inhibitors (MAOI) (4, 7.1) 5.5 Long-Term Suppression of Growth in Pediatric Patients ----WARNINGS AND PRECAUTIONS----

Risks to Patients with Serious Cardiac Disease: Avoid use in patients with known structural cardia abnormalities, cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, or othe serious cardiac disease. (5.2)

Increased Blood Pressure and Heart Rate: Monitor blood pressure and pulse at appropriate Psychiatric Adverse Reactions: Prior to initiating dextroamphetamine saccharate, amphetamine

aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules, screen patients for risk factors for developing a maric episode. If new psychotic or maric symptoms occur, consider discontinuing dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules, (5.4) Long-Term Suppression of Growth in Pediatric Patients: Closely monitor growth (height and weight) in pediatric patients. Pediatric patients not growing or gaining height or weight as expected may need to have their treatment interrupted. (5.5)

Seizures: May lower the convulsive threshold. Discontinue in the presence of seizures. (5.6) Secures, way lower the convolute interaction biscontinue in the presence of secures, (i.e., Peripheral Vasculopathy, Including Raynaud's Phenomenon: Careful observation for digital changes is necessary during dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for patients who develop signs or symptoms of peripheral vasculopathy. (5.7)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. If it occurs, discontinue dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules and initiate supportive treatment. (4, 5.8, 10)

Motor and Verbal Tics, and Worsening of Tourette's Syndrome: Before initiating dextroamphetaming saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules, assess the family history and clinically evaluate patients for tics or Tourette's syndrome. Regularly monitor patients for the emergence or worsening of tics or Tourette's syndrome. Discontinue treatment if clinically appropriate. (5.9)

10/2023 -----ADVERSE REACTIONS-----10/2023

- Pediatric patients ages 6 to 12: Most common adverse reactions (≥5% and with a higher incidence than on placebo) were loss of appetite, insomnia, abdominal pain, emotional lability, vomiting, nervousness, nausea, and fever. (6.1) 10/2023 10/2023
 - Pediatric patients ages 13 to 17: Most common adverse reactions (≥5% and with a higher incidence than on placebo) were loss of appetite, insomnia, abdominal pain, weight loss, and nervousness.
 - Adults: Most common adverse reactions ≥5% and with a higher incidence than on placebo were dry mouth, loss of appetite, insomnia, headache, weight loss, nausea, anxiety, agitation, dizziness, tachycardia, diarrhea, asthenia, and urinary tract infections. (6.1)
 - To report SUSPECTED ADVERSE REACTIONS contact Camber Pharmaceuticals Inc. at 1-866-495-

8330 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. -----DRUG INTERACTIONS------

- Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (2.7, 7.1)
- Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7.1) ------USE IN SPECIFIC POPULATIONS----
- Pregnancy: May cause fetal harm. (8.1)
- Lactation: Breastfeeding not recommended. (8.2)
- See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

7 DRUG INTERACTIONS

7.1 Clinically Important Interactions with Amphetamines 7.2 Drug-Laboratory Test Interactions **8 USE IN SPECIFIC POPULATIONS** 8.1 Pregnancy 8.2 Lactation 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Renal Impairment 9 DRUG ABUSE AND DEPENDENCE 9.1 Controlled Substance 9.2 Abuse 9.3 Dependenc 10 OVERDOSAGE

11 DESCRIPTION 12 CLINICAL PHARMACOLOG

12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics

- **13 NONCLINICAL TOXICOLOGY**
- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2 Animal Toxicology and/or Pharmacology
- 14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.

3 DOSAGE FORMS AND STRENGTHS

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules are available as:

5 mg extended release capsules: Hard Gelatin Capsule Shell Size "3" Blue Opaque Cap and Clear transparent body, imprinted with "5 mg" on cap and "T" on body in black ink filled with light to dark beige colored spherical pellets.

10 mg extended release capsules: Hard Gelatin Capsule Shell Size "3" Blue Opaque Cap and Blue transparent body, imprinted with "10 mg" on cap and "T" on body in black ink filled with light to dark beige colored spherical pellets. 15 mg extended release capsules: Hard Gelatin Capsule Shell Size "2" White Onaque Cap and Blue

nt body, imprinted with "15 mg" on cap and "T" on body in black ink filled with light to dark beige colored spherical pellets. 20 mg extended release capsules: Hard Gelatin Capsule Shell Size "2" Orange Opaque Cap and Orange

transparent body, imprinted with "20 mg" on cap and "T" on body in black ink filled with light to darl beige colored spherical pellets. 25 mg extended release capsules: Hard Gelatin Capsule Shell Size "1" White Opaque Cap and Orange transparent body, imprinted with "25 mg" on cap and "T" on body in black ink filled with light to dark

beige colored spherical pellets. 30 mg extended release capsules: Hard Gelatin Capsule Shell Size "1" Yellow Opague Cap imprinted with and White Opaque body imprinted with "T" in black ink filled with light to dark beige colored

CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients. Closely monitor growth (weight and height) in dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules-treated pediatric patients treated with CNS stimulants.

In a controlled trial of dextocamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules in adolescents, mean weight change from baseline within the initial 4 weeks of therapy was -1.1 lbs. and -2.8 lbs., respectively, for patients receiving 10 and 20 mg dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules. Higher doese were associated with greater weight loss within the initial 4 weeks of treatment. Chronic use of amphetamines can be expected to cause a similar suppression of growth [see Adverse Reactions (6.11)].

Pediatric patients who are not growing or gaining weight as expected may need to have their treatment

5.6 Seizures

There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in the absence of seizures, and very rarely, in Instory or servates, in patients with prior Eco annonitatives in the absence or servates, and very ratery, in patients without a history of seizures and no prior EEG evidence of seizures. In the presence of seizures dextroamphetamine suchates, amphetamine aspartate monohydrate, dextroamphetamine sulfate amphetamine sulfate extended-release capsules should be discontinued.

5.7 Peripheral Vasculopathy, Including Raynaud's Phenomenor

5.7 Perpheral vasculopatry, including kaynaud's Prenomenon CNS stimulants, including dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud's phenomenon. Signs and symptoms are usually intermittent and mild; however, sequelae have included digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud's phenomenon, were observed in post-marketing reports and at the therapeutic dosage of CNS stimulants in all age groups throughout the course of treatment. Signs and symptoms generally improved after dosage reduction or discontinuation of the CNS stimulant.

Careful observation for digital changes is necessary during dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for dextroamphetamine sucharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate exchanged and the extended-release capsules-treated patients who develop signs or symptoms of preintegrutement and the extended-release capsules-treated patients who develop signs or symptoms of preintegrutements. nerinheral vasculopathy

5.8 Serotonin Syndrome

Revised: 09/24

5.8 Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as MAOIs, selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fertanyl, ithium, tramadol, tryptophan, buspirone, and SL John's Wort [see Drug Interactions (7.1)]. Amphetamines and amphetamine derivatives are known to be metabolized, to some degree, by cytochrome P450 206 (CYP2D6) and display minor inhibition of CYP2D6 metabolism [see Clinical Pharmacology (12.3)]. The potential for a pharmacokinetic interaction exists with the coadministration of CYP2D6 inhibitors which may increase the risk with increased exposure to dextroamphetamine saaccharate, amphetamine essituations, consider an alternative nonserotonergic drug or an alternative drug that does not inhibit CYP2D6 [see Drug Interactions (7.1)]. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, flushing, hyperthermia), neuromuscular symptoms (e.g., remor, rigidity, myocionus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Concomitant use of dextroamphetamine saccharate, amphetamine aspartate monohydrate

sulfate, amphetamine sulfate extended-release capsules with MAOI drugs is ontraindicated Isee Contraind lications (4)1.

Discontinue treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate Discontinue treatment with textuality textual pretaining saccharate, ampretaining aspartate monolity area dextroamphetamine sulfate extended-release capsules and any concomitant serotonergic agents immediately if symptoms of serotonin syndrome occur, and initiate supportive symptomatic treatment. Concomitant use of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules with other serotonergic drugs or CVP2D6 inhibitors should be used only if the potential benefit justifies the potential text. If define accelerate initiating dextreamphetamine accelerate accelerate and relevant text. risk. If clinically warranted, consider initiating dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules with lower doese, monitoring patients for the emergence of serotonin syndrome during drug initiation or titration, and informing patients of the increased risk for serotonin syndrome.

5.9 Motor and Verbal Tics, and Worsening of Tourette's Syndrome

CNS stimulants, including amphetamine, have been associated with the onset or exacerbation of motor nd verbal tics. Worsening of Tourette's syndrome has also been reported [see Adverse Reactions (6.2)]. Before initiating dextroamphetamine saccharate, amphetamine aspartate monohydrate dextroamphetamine sulfate, amphetamine sulfate extended-release capsules, assess the family history and clinically evaluate patients for tics or Tourette's syndrome. Regularly monitor dextroamphetamine saccharate, amphetamine sapartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules-treated patients for the emergence or worsening of tics or Tourette's syndrome, and discontinue treatment if clinically appropriate.

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

aboratory analyses, and ECGs.

7/259) receiving placebo.

The following adverse reactions are discussed in greater detail in other sections of the labeling: Abuse, Misuse, and Addiction [see Boxed Warning, Warnings and Precautions (5.1), Drug Abuse and Dependence (9.2, 9.3)]

Long-Term Suppression of Growth in Pediatric Patients [see Warnings and Precautions (5.5)]

Peripheral Vasculopathy, including Raynaud's Phenomenon [see Warnings and Precautions (5.7)]

Motor and Verbal Tics, and Worsening of Tourette's Syndrome [see Warnings and Precautions (5.9)]

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in

the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The premark the rates observed in practice. The premarketing development program for dextroamphetamine suffate extended-release capsules included exposures in a total of 1,315 participants in clinical trials (635 pediatric patients, 350 adolescent patients, 248 adult patients, and 82 healthy adult subjects). Of these, 635 patients (ages 6 to 12) were evaluated in two controlled clinical studies, one open-label clinical study, and two single-dose clinical pharmacology studies (N=40). Safety data on all patients are included in the discussion that follows. Adverse reactions were assessed by collecting adverse reactions, results of physical examinations, vital signs, weights, laboratory analyses, and ECSs.

Adverse reactions during exposure were obtained primarily by general inquiry and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse reactions without first grouping similar types of reactions into a smaller number of standardized event categories. In the tables and listings that follow, COSTART terminology has been used to classify reported adverse reactions.

The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed.

to be instantiant example to be added to a specific the second state of the second sta

The most frequent adverse reactions leading to discontinuation of dextroamphetamine saccharate

Increased Blood Pressure and Heart Rate [see Warnings and Precautions (5.3)]

Risks to Patients with Serious Cardiac Disease [see Warnings and Precautions (5.2)]

Serotonin Syndrome [see Warnings and Precautions (5.8)]

Seizures [see Warnings and Precautions (5.6)]

Adverse Reactions Leading to Discontinuation of Treatment

Psychiatric Adverse Reactions [see Warnings and Precautions (5.4)]

I INDICATIONS AND USAGE

1.1 Attention Deficit Hyperactivity Disorder

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older.

2 DOSAGE AND ADMINISTRATION

2.1 Pretreatment Screening

Prior to treating patients with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules, assess:

- for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) [see Warnings and Precautions (5.2)].
- the family history and clinically evaluate patients for motor or verbal tics or Tourette's syndrome before initiating dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules [see Warnings and Precautions (5.9)].

2.2 General Administration Informatio

Individualize the dosage according to the therapeutic needs and response of the patient. Administe Individualize the obsage according to the therapeuty needs and response or lextroamphetamine saccharate, amphetamine aspartate monohydrate, dext amphetamine sulfate extended-release capsules at the lowest effective dosage. nine sulfate

Based on bioequivalence data, patients taking divided doses of immediate-release dextroamphetamin saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate tablets, (for example, twice daily), may be switched to dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules at the same total daily dose taken once daily. Titrate at weekly intervals to appropriate efficacy and tolerability as indicated

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules may be taken whole, or the capsule may be opened and the entire contents sprinkled on applesauce. If the patient is using the sprinkle administration method, the sprinkled applesauce should be consumed immediately; it should not be stored. Patients should take the applesauce with sprinkled beads in its entirety without chewing. The dose of a single capsule should not be divided. The contents of the entire capsule should be taken, and patients should not take anything less than one cansule pare day. less than one capsule per day.

Dextroamphetamine saccharate amphetamine aspartate monohydrate, dextroamphetamine sulfate release capsules may be taken orally with or without food

Dextroamphetamine saccharate amphetamine aspartate monohydrate dextroamphetamine sulfate ease capsules should be given upon awakening. Afternoon doses 5.2 Risks to Patients with Serious Cardiac Disease nine sulfate extended-re should be avoided because of the potential for insomnia

2.3 Recommended Dosage in Pediatric Patients 6 to 12 Years

2.5 Recommenced busget in reductive Paralate Factors to 0.12 tears in pediatric patients 6 to 12 years of age with ADHD and are either starting treatment for the first time or switching from another medication, start with 10 mg once daily in the morning; daily dosage may be adjusted in increments of 5 mg or 10 mg at weekly intervals. When in the judgment of the clinician a lower initial dose is appropriate, patients may begin treatment with 5 mg once daily in the morning. The maximum recommended dose for children 6 to 12 years of age is 30 mg/day; doses greater than 30 mg/day have not been studied in children. Dextroamphetamine sucharte, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules has not been studied in children under Socie. monohydrate, dextroamphetamine sulta studied in children under 6 years of age

2.4 Recommended Dosage in Pediatric Patients 13 to 17 Years

The recommended starting dose for pediatric patients 13 to 17 years of age with ADHD and are either starting treatment for the first time or switching from another medication is 10 mg/day. The dose may be increased to 20 mg/day after one week if ADHD symptoms are not adequately controlled.

2.5 Recommended Dosage in Adults

In adults with ADHD who are either starting treatment for the first time or switching from another herd dose is 20 mg

2.6 Dosage in Patients with Renal Impairment

2.6 Doságe in ratients with severe renal impairment In adult patients with severe renal impairment (GFR 15 to <30 mL/min/1.73 m²), the recommended dose is 15 mg once daily in the morning. In pediatric patients (6 to 17 years of age) with severe renal impairment, the recommended dose is 5 mg once daily. Dextroamphetamine saccharate, amphetamine executed execution of the exe aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules are not recommended in patients with end stage renal disease (ESRD) (GFR <15 mL/min/1.73 m²) *[see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].*

2.7 Dosage Modification Due to Drug Interactions

Agents that alter urinary pH can impact excretion and alter blood levels of amphetamines. Acidifying regents data date unimary per ampter structure and data to solve to tag or amphetamines. Actanging agents (e.g., accorbic acid) decrease blood levels, adjust dextramphetamine sulfate amphetamines aspartate monohydrate, dextroamphetamine sulfate, amphetamines sulfate extended-release capsules dosage based on clinical response [see Trug Interactions (7)].

4 CONTRAINDICATIONS

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules administration is contraindicated in patients:

- known to be hypersensitive to amphetamine, or other components of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules. Hypersensitivity reactions such as angloedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Provider 4: 0]
- taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hyperte crisis [see Warnings and Precautions (5.8), Drug Interactions (7.1)]

5 WARNINGS AND PRECAUTIONS 5.1 Abuse, Misuse, and Addiction

5.1 Abuse, Misuse, and Addiction Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules has a high potential for abuse and misuse. The use of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Dextroamphetamine sulfate extended-release capsules exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Dextroamphetamine sulfate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules can be diverted for non-medical use into illicit channels or distribution (see Drug Abuse and Dependence (9.2)). Misuse and abuse of CNS stimulants, including dextroamphetamine sulfate extended-release capsules, can result in overdose and death (see Overdosage (10)), and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.

Before prescribing dextroamphetamine saccharate, amphetamine aspartate monohydrate Ifate, amphetamine sulfate extended-release capsules, assess each patient's risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients to store dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules in a safe place, preferably locked, and instruct patients to not give dextroamphetamine saccharate, amphetamine spartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules o anvone else. Throughout dextroamphetamine saccharate, amphetamine aspartate monohydrate mine sulfate, amphetamine sulfate extended-rele se capsules treatment, rea patient's risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse nisuse and addiction

Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who were treated with CNS stimulants at the recommended ADHD dosage. Avoid dextroamphetamine sulfate extended-release capsules use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease.

5.3 Increased Blood Pressure and Heart Rate

CNS stimulants may cause an increase in blood pressure (mean increase approximately 2 to 4 mmHg) and heart rate (mean increase approximately 3 to 6 bpm).

Monitor all dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules-treated patients for hypertension and tachycardia

5.4 Psychiatric Adverse Reactions Exacerbation of Pre-Existing Psychosis

Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with pre-existing psychotic disorde

Induction of a Manic Episode in Patients with Bipolar Disease

CNS stimulants may induce a manic or mixed episode in patients. Prior to initiating dextroamphetamine saccharate, amphétamine aspartate monohydrate, dextroamphetamine sulfate, amphétamine sulfate extended-release capsules treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, or lepression).

New Psychotic or Manic Symptoms

CNS stimulants, at the recommended dosage, may cause psychotic or manic symptoms (e.g. CNS sumulants, at the recommended dosage, may cause psychold or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania. In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants, psychotic or manic symptoms occurred in approximately 0.1% of CNS stimulant-treated patients compared to 0% of placebo-treated patients. If such symptoms occur, consider discontinuing dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules.

The most frequent adverse reactions leading to discontinuation of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules in controlled and uncontrolled, multiple-dose clinical trials of children (N=595) were anorexia (loss of appetite) (2.9%), insomnia (1.5%), weight loss (1.2%), emotional lability (1%), and depression (0.7%). Over half of these patients were exposed to dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules for 12 months or more.

In a separate placebo-controlled 4 week study in adolescents with ADHD five patients (2.1%) ment due to adverse events among dextroamphet nine saccharate amphe aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules eated patients (N=233) compared to one who received placebo (N=54) The most frequent adverse went leading to discontinuation and considered to be drug-related (i.e., leading to discontinu ion in a east 1% of dextroamphetamine saccharate, amphetar nine aspartate monohydrate, dextroampheta ulfate, amphetamine sulfate extended-release capsules-treated patients and at a rate at least twice that of placebo) was insomnia (1.3%, n=3).

In one placebo-controlled 4 week study among adults with ADHD with doses 20 mg to 60 mg, 23 patients (12.0%) discontinued treatment due to adverse events among dextroamphetamine saccharate amphetamine aspartate monolydrate, dextroamphetamine sulfate, amphetamine sulfate. Methemine sulfate Methed4 release capsules-treated patients (M=191) compared to one patient (1.6%) who received placebo (N=64) The most frequent adverse events leading to discontinuation and considered to be drug-related (i.e., leading to discontinuation in at least 1% of dextroamphetamine sucharate, amphetamine aspartate monohydrate, dextroamphetamine suffate, amphetamine suffate extended-release capsules-treated patients and at a rate at least twice that of placebo) were insomnia (5.2%, n=10), anxiety (2.1%, n=4), nervousness (1.6%, n=3), dry mouth (1.6%, n=3), norexia (1.6%, n=3), tachycardia (1.6%, n=3), headache (1.6%, n=3), and asthenia (1.0%, n=2).

Adverse Reactions Occurring in Controlled Trials

Body Sys

Adverse reactions reported in a 3 week clinical trial of children and a 4 week clinical trial in adolescents respectively, treated with dextroamphetamine saccharate, amphetamine aspartate dextroamphetamine sulfate, amphetamine sulfate extended-release capsules or placebo nted in the tables below

Table 1: Adverse Reactions Reported by 2% or More of Children (6 to 12 Years Old) Receivin Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate Amphetamine Sulfate Extended-Release Capsules with Higher Incidence Than on Placebo in a 584 Patient Clinical Study

Body System	Preferred Term	Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate Extended-Release Capsules (n=374)	Placebo (n=210)
General	Abdominal Pain		
	(stomach ache)	14%	10%
	Fever	5%	2%
	Infection	4%	2%
	Accidental Injury	3%	2%
	Asthenia (fatigue)	2%	0%
Digestive System	Loss of Appetite	22%	2%
	Vomiting	7%	4%
	Nausea	5%	3%
	Dyspepsia	2%	1%
Nervous System	Insomnia	17%	2%
	Emotional Lability	9%	2%
	Nervousness	6%	2%
	Dizziness	2%	0%
Metabolic/ Nutritional	Weight Loss	4%	0%

Table 2: Adverse Reactions Reported by 5% or More of Adolescents (13 to 17 Years Old) Weighi ⊴75 kg/165 lbs Receiving Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydra Dextroamphetamine Sulfate, Amphetamine Sulfate Extended-Release Capsules with Higl Incidence Than Placebo in a 287 Patient Clinical Forced Weekly-Dose Titration Study*

item	Preferred Term	Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate Extended-Release Capsules (n=233)	Placebo (n=54)
	Abdominal Pain (stomach ache)	11%	2%

concomitant serotonergic drug(s) [see Warnings and Precautions (5.8 CYP2D6 Inhibitors

> The concomitant use of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules and CYP2D6 inhibitors may increase the exposure of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate amphetamine sulfate extended-release capsules compared to the use of the drug alone and increase the risk of serotonin syndrome.

> Initiate with lower doses and monitor patients for signs and symptoms of serotoni syndrome particularly during dextroamphetamine saccharate, amphetamine aspartate nonohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules and the CYP2D6 inhibitor [see Warnings and Precautions (5.8), Overdosage (10)].

Alkalinizing Agents

Clinical Impact Increase blood levels and potentiate the action of amphetamine.

Coadministration of dextroamphetamine saccharate, amphetamine aspartat monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-releas ervention capsules and gastrointestinal or urinary alkalinizing agents should be avoided.

Acturiying Agents						
Clinical Impact	Lower blood levels and efficacy of amphetamines.					
Intervention Increase dose based on clinical response.						
Tricyclic Antide	Tricyclic Antidepressants					
Clinical Impact	May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated.					

Intervention Monitor frequently and adjust or use alternative therapy based on clinical response. **Proton Pump Inhibitors** Clinical Impact Time to maximum concentration (T_{max}) of amphetamine is decreased compared to when administered alone. Monitor patients for changes in clinical effect and adjust therapy based on clinica Intervention response. 7.2 Drug-Laboratory Test Interactions

Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening. Amphetamines may interfere with urinary sternid determinations

8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy

Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to saccharate, amp amine aspartate monohydrate, dextroampheta amphetamine sulfate extended-release capsules during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychostimulants at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/ Risk Summary

Available data from published epidemiologic studies and postmarketing reports on use of prescription amphetamine in pregnant women have not identified a drug-associated risk of major birth defects and miscarriage (see *Data*). Adverse pregnancy outcomes, including premature delivery and low birth weight, have been seen in infants born to mothers taking amphetamines during pregnancy (see *Clinica Considerations*).

No apparent effects on morphological development were observed in embryo-fetal development studies No apparent effects on morphological development were observed in embryo-fetal development studies, with oral administration of amphetamine to rats and rabbits during organogenesis at doses 2 and 12 times, respectively, the maximum recommended human dose (MRHD) of 20 mg/day given to adolescents, on a mg/m² basis. However, in a pre- and postnatal development study, amphetamine (4 to 1 - ratio of 3:1) administreted orally to pregnant rats during gestation and lactation caused a decrease in pup survival and a decrease in pup body weight that correlated with a delay in developmental landmarks at clinically relevant doses of amphetamine. In addition, adverse effects on reproductive performance were observed in pups whose mothers were treated with amphetamine. Long-term neurochemical and behavioral effects have also been reported in animal developmental studies using clinically relevant doses of amphetamine. ine (see Data)

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically amphetamine sulfate extended-release capsules may produce physical dependence. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant do reduction of a drug.

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate

Withdrawal signs and symptoms after abrupt discontinuation or dose reduction following prolonged use of CNS stimulants including dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules include dysphoric mood; depression; ratigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation.

Tolerance

9.3 Dependence

Physical Dependence

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules may produce tolerance. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).

10 OVERDOSAGE

Clinical Effects of Overdose

recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

locomotor activity, and changes in sexual function

Amphetamines, such as dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules, cause vasoconstriction and thereby may decrease placental perfusion. In addition, amphetamines can stimulate uterine contractions, increasing the risk of premature delivery. Infants born to mothers taking amphetamines during pregnancy have an increased risk of premature delivery and low birth weight.

Monitor infants born to mothers taking amphetamines for symptoms of withdrawal such as feeding difficulties, irritability, agitation, and excessive drowsiness.

Animal Data Amphetamine (d- to I- enantiomer ratio of 3:1) had no apparent effects on embryofetal morphological development or survival when administered orally to pregnant rats and rabbits throughout the period of organogenesis at doses of up to 6 and 16 mg/kg/day, respectively. These doses are approximately 2 and 12 times, respectively, the maximum recommended human dose (MRHD) of 20 mg/day given to adolescents, on a mg/m² basis. Fetal malformations and death have been reported in mice following parenteral administration of 4-amphetamine doses of 50 mg/kg/day (approximately 10 times the MRHD given to adolescents on a mg/m² basis) or greater to pregnant animalis. Administration of these doses was also associated with severe maternal toxicity.

also associated with severe maternal toxicity. A study was conducted in which pregnant rats received daily oral doses of amphetamine (d- to l-enantiomer ratio of 3:1) of 2, 6, and 10 mg/kg from gestation Day 6 to lactation Day 20. These doses are approximately 0.8, 2, and 4 times the MRH0 of 20 mg/day given to adolescents, on a mg/m² basis. All doses caused hyperactivity and decreased weight gain in the dams. A decrease in pup survival was seen at all doses. A decrease in pup body weight was seen at 6 and 10 mg/kg which correlated with delays in developmental landmarks, such as preputial separation and vaginal opening. Increased pup locomotor activity was seen at 10 mg/kg on Day 22 postpartum but not at 5 weeks postweaning. When pups were tested for reproductive performance at maturation, gestational weight gain, number of implantations, and number of delivered pups were decreased in the group whose mothers had been given 10 mg/kg.

A number of studies from the literature in rodents indicate that prenatal or early postnatal exposure to

amphetamine (d- or d, l-) at doses similar to those used clinically can result in long-term neurochemical and behavioral alterations. Reported behavioral effects include learning and memory deficits, altered

hisk summary Based on limited case reports in published literature, amphetamine (d- or d, l-) is present in human milk, at relative infant doses of 2 to 13.8% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.9 and 7.5. There are no reports of adverse effects on the breastfed infant. Long-term neurodevelopmental effects on infants from amphetamine exposure are unknown. It is possible that large dosages of amphetamine might interfere with milk production, especially in women whose lactation is not well established. Because of the potential for serious adverse reactions in nursing infants, advise patients that breastfeeding is not recommended during treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release cansules.

The safety and effectiveness of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules have been established in pediatric patients with ADHD 6 years of age and older.

The safety and efficacy of dextroamphetamine saccharate, amphetamine aspartate monohydrate dextroamphetamine sulfate, amphetamine sulfate extended-release capsules in pediatric patients less than 6 years of age have not been established. Long-term effects of amphetamines in pediatric patients has not been well established.

Growth should be monitored during treatment with stimulants, including dextroamphetamine saccharate

ampletamine aspartate monohydrate, dextroampletamine sulfate, ampletamine sulfate extended-release capsules, and pediatric patients aged 6 to 17 years who are not growing or gaining weight as expected may need to have their treatment interrupted [see Warnings and Precautions (5.5)].

Juvenile rats treated with mixed amphetamine salts early in the postnatal period through sexual

avenier fats dealed with initized ampletanime saits early in the positizatia period unough sexual autration demonstrated transient changes in motor activity. Learning and memory was impaired at proximately 6 times the maximum recommended human dose (MRHD) given to children on a mg /² basis. No recovery was seen following a drug-free period. A delay in sexual maturation was observed t a dose approximately 6 times the MRHD given to children on a mg/m² basis, although there was no

In a juvenile developmental study, rats received daily oral doses of amphetamine (d to Lenantiomer ratio of

3:1) of 2, 6, or 20 mg/kg on Days 7 to 13 of age; from Day 14 to approximately Day 60 of age these doses were given b.i.d. for total daily doses of 4, 12, or 40 mg/kg. The latter doses are approximately 0.6, 2, and

Were given D.C. or total daily does to 4, 12, or 40 mg/kg. The fatter does are approximately to 5, 2, and 6 times the MRHD of 30 mg/da, given to children on a mg/m² basis. Postdosing hyperactivity was seen at all doses; motor activity measured prior to the daily dose was decreased during the dosing period but the decreased motor activity was largely absent after an 18 day drug-free recovery period. Performance in the Morris water maze test for learning and memory was impaired at the 40 mg/kg dose, and sporadically at the lower doses, when measured prior to the daily dose during the treatment period, no recovery was seen the face 40 dose and the dose of the dose of the daily dose during the treatment period.

after a 19 day drug-free period. A delay in the developmental milestones of vaginal opening and preputial

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules has not been studied in the geriatric population.

Due to reduced clearance of amphetamines in patients with severe renal impairment (GFR 15 to <30 mL/ bit of rotated attack of antibications of matching attacks where the monomer and the second second attack of antibication of the second second

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules contains amphetamine, a Schedule II controlled

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate ampletamine sulfate extended-release capsules has a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction *[see Warnings and Precautions* [5.1]). Extramphetamine sucharate, ampletamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules can be diverted for non-medical use into illicit

Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or

Aduse is the interview of the second of the

Mususe and abuse or ampinetamine may cause increased near rate, respiratory rate, or ploop pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse. Misuse and abuse of CNS stimulants, including dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules, can result in overdose and death *[see Overdosage (10)]*, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.

Misuse and abuse of amphetamine may cause increased heart rate, respiratory rate,

separation was seen at 40 mg/kg but there was no effect on fertility.

Clinical Considerations

Fetal/Neonatal Adverse Reactions

2%

4%

6%a

0%

ne sulfati

(n=64)

13% 5%

5%

3%

3% 0%

13% 5%

5% 0%

13%a

3%

0%

0%

ne sulfate

Data

Animal Data

8.2 Lactation

Risk Summary

8.4 Pediatric Use

Long-Term Growth Suppression

Juvenile Animal Toxicity Data

8.5 Geriatric Use

8.6 Renal Impairment

(2.6), Clinical Pharmacology (12.3)].

9 DRUG ABUSE AND DEPENDENCE

d-Amphetamine is not dialyzable

9.1 Controlled Substance

channels or distribution

substance.

9.2 Abuse

12%

6%

9%

Dextroamphetamine Saccharate, phetamine Aspartate Mo

Dextroamphetamine Sulfate and

Release Capsules

(n=191)

26%

35%

33%

8% 6%

27%

8%

8% 7%

13%

6%

10%

5%

ering, excessive speech), palpitation, twitching

mine Sulfate Exter

Note: The following reactions did not meet the criterion for inclusion in Table 2 but were reported by 2 to 4% of adolescen

nphetamine saccharate, amphetamine aspartate monohydrate, dex

amphetamine sulfate extended-release capsules with a higher incidence than patients receiving placebo in this study

accidental injury, asthenia (fatigue), dry mouth, dyspepsia, emotional lability, nausea, somnolence, and vomiting

Table 3: Adverse Reactions Reported by 5% or More of Adults Receiving Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended-Release Capsules with Higher Incidence Than on Placebo in a 255 Patient Clinical Forced Weekly-Dose Titration Study*

Note: The following reactions did not meet the criterion for inclusion in Table 3 but were reported by 2 to 4% of adult

ence, speech disorder (e.g., stutt

Invertension In a controlled 4 week outpatient clinical study of adolescents with ADHD, isolated systolic blood pressure elevations ≥15 mmHg were observed in 7/64 (11%) placebo-treated patients and 7/100 (7%) patients receiving dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules 10 or 20 mg. Isolated elevations in diastolic blood pressure ≥8 mmHg were observed in 16/64 (25%) placebo-treated patients and 22/100 (22%) dextroamphetamine sulfate extended-release capsules-traate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules-treated patients. Similar results were observed at higher doese. *Isee Warnings and Precautions* (5.21)

In a single-dose pharmacokinetic study in 23 adolescents with ADHD, isolated increases in systolic blood pressure (above the upper 95% CI for age, gender, and stature) were observed in 2/17 (12%) and 8/23 (35%), subjects administered 10 mg and 20 mg dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sufface extended-release capsules, respectively. Higher single doses were associated with a greater increase in systolic blood pressure. All increases were transient, appeared maximal at 2 to 4 hours postdose and, not associated with symptoms.

6.2 Adverse Reactions Associated with the Use of Amphetamine, Dextroamphetamine Saccharate Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended-Release Capsules, or Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate Tablets

The following adverse reactions have been identified during postapproval use of amphetamin

The norwing advice tractaries match beck international advices of mapped to the second second advices of mapped and the second s

Allergic: Urticaria, rash, hypersensitivity reactions including angioedema and anaphylaxis. Serious skin rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported.

Cardiovascular: Palpitations. There have been isolated reports of cardiomyopathy associated with chronic

Central Nervous System: Psychotic episodes at recommended doses, overstimulation, restlessness irritability, euphoria, dyskinesia, dysphoria, depression, tremor, motor and verbal tics, aggression, ange logorrhea, dermatillomania, paresthesia (including formication), and bruxism.

Gastrointestinal: Unpleasant taste, constipation, intestinal ischemia, and other gastrointestinal

Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis

Do not administer dextroamphetamine saccharate, amphetamine aspartate

onohydrate, dextroamphetamine sulfate, amphetamine sulfate extend lease capsules concomitantly or within 14 days after discontinu

Clinical Impact Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure.

The concomitant use of dextroamphetamine saccharate, amphetan

capsules and serotonergic drugs increases the risk of serotonin syndrome.

Initiate with lower doses and monitor patients for signs and symptoms of seroto

syndrome, particularly during dextroamphetamine saccharate, amphetamin

aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended

release capsules initiation or dosage increase. If serotonin syndrome occurs.

discontinue dextroamphetamine saccharate, amphetamine aspartate monohydrate

dextroamphetamine sulfate, amphetamine sulfate extended-release capsules and the

Clinical Impact monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-releas

estimate their frequency or establish a causal relationship to drug exposure

Endocrine: Impotence, changes in libido, frequent or prolonged erections.

Table 4 Drugs Having Clinically Important Interactions with Amphetamines

Musculoskeletal and Connective Tissue Disorders: Rhabdomvolvsis.

MAOI [see Contraindications (4)].

7.1 Clinically Important Interactions with Amphetamines

amphetamine sulfate extended-release capsules with a higher incidence than patients receiving placebo in this stud

infection, photosensitivity reaction, constipation, tooth disorder (e.g., teeth clenching, tooth infection), emotion

patients receiving dextroamphetamine saccharate, amphetamine aspartate monohydrate, dex

Overdose of CNS stimulants is characterized by the following sympathomimetic effects:

Cardiovascular effects including tachyarrhythmias, and hypertension or hypotension. Vasospasm, myocardial infarction, or aortic dissection may precipitate sudden cardiac death. Takotsubo cardiomyopathy may develop.

CNS effects including psychomotor agitation, confusion, and hallucinations. Serotonin syndrome, seizures, cerebral vascular accidents, and coma may occur.

Life-threatening hyperthermia (temperatures greater than 104°F) and rhabdomyolysis may develop. Overdose Management

Consider the possibility of multiple drug ingestion. The pharmacokinetic profile of dextroamphe saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules should be considered when treating patients with overdose. D-amphetamine is not dialyzable. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendation

11 DESCRIPTION

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine DeAtOvaniphetanime sacuralatie, aniphetanime aspariate intronorytice, beato complementation sulfate and ampitetamine sulfate extended-release capsules contain mixed satis of a single-entity amphetamine, a CNS sulfate and amphetamine saccharate, amphetamine asparate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules contains equal amounts (by weight) of four salts: dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate and amphetamine (D,L)-aspartate monohydrate. This results in a 3.1:1 mixture of dextro- to levo- amphetamine base equivalent

The 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg strength extended release capsules are for oral administration. Dextroamphetamine saccharate, amphetamine aspartate monohydrate, for oral administration. Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules contains two types of drug-containing beads (immediate-release and delayed release) which prolong the release of amphetamine compared to the dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate (immediate-release) tablet formulation

Each capsule contains:

Capsule Strength	5 mg	10 mg	15 mg	20 mg	25 mg	30 mg
Dextroamphetamine Saccharate	1.25 mg	2.5 mg	3.75 mg	5.0 mg	6.25 mg	7.5 mg
Amphetamine (D,L)-Aspartate Monohydrate	1.25 mg	2.5 mg	3.75 mg	5.0 mg	6.25 mg	7.5 mg
Dextroamphetamine Sulfate	1.25 mg	2.5 mg	3.75 mg	5.0 mg	6.25 mg	7.5 mg
Amphetamine Sulfate	1.25 mg	2.5 mg	3.75 mg	5.0 mg	6.25 mg	7.5 mg
Total amphetamine base equivalence	3.1 mg	6.3 mg	9.4 mg	12.5 mg	15.6 mg	18.8 mg
<i>d</i> -amphetamine base equivalence	2.4 mg	4.7 mg	7.1 mg	9.5 mg	11.9 mg	14.2 mg
<i>I</i> -amphetamine base equivalence	0.75 mg	1.5 mg	2.3 mg	3.0 mg	3.8 mg	4.5 mg
Inactive Ingredients and Colors						

The inactive ingredients in dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules include: Sugar spheres, hydroxy propyl methyl cellulose, talc, triethyl citrate, methacrylic acid-ethyl acrylate copolymer, hard gelatin capsules, titanium dioxide, polyethylene glycol, iron oxide yellow, polysorbate 80, iron oxide red. The 5 mg capsule shell contain Titanium dioxide, FD & C Blue 1, FD & C Red 40, gelatin and sodium lauryl sulfate. The 10 mg capsule shell contain Titanium dioxide, FD & C Blue 1, FD & C Red 40, gelatin, sodium



12.1 Mechanism of Action

Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known.


12.2 Pharmacodynamics

12.3 Pharmacokinetics

Pharmacokinetic studies of dextroamphetamine saccharate, amphetamine aspartate monohydrate, Pharmacokinetic studies of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine suifate ka, amphetamine suifate extended-release capsules have been conducted in healthy adult and pediatric (children aged 6 to 12 yrs) subjects, and adolescent (13 to 17 yrs), and children with ADHD. Both dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate tablets (immediate-release) and dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine aspartate monohydrate, extended-release capsules contain d-amphetamine and I-amphetamine aspartate monohydrate, dextroamphetamine aspartate, amphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine aspartate, amphetamine sulfate tablets (immediate-release), the peak plasma concentrations occurred in about 3 hours for both d-amphetamine and I-amphetamine.

The time to reach maximum plasma concentration (T_{max}) for dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules is about 7 hours, which is about 4 hours longer compared to dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate tablets (immediate-release). This is consistent with the extended-release nature of the product.

Figure 1: Mean d-amphetamine and I-amphetamine Plasma Concentrations Following Administration of Dextroampletamine Saccharate, Ampletamine Aspartate Monohydrate, Dextroampletamine Sulfate, Ampletamine Sulfate Extended-Release Capsules 20 mg (8 am) and Dextroampletamine Saccharate, Ampletamine Aspartate Monohydrate, Dextroampletamine Sulfate, Ampletamine Sulfate, Su



A single dose of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate 20 mg extended-release capsules provided comparable plasma concentration profiles of both d-amphetamine and I-amphetamine to dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate tablets (immediate-release) 10 mg twice daily administered 4 hours apart.

The mean elimination half-life for d-amphetamine is 10 hours in adults; 11 hours in adolescents aged 13 to 17 years and weighing less than or equal to 75 kg/165 lbs; and 9 hours in children aged 6 to 12 years. For the I-amphetamine, the mean elimination half-life in adults is 13 hours; 13 to 14 hours in adolescents; and 11 hours in children aged 6 to 12 years. On a mg/kg body weight basis, children have a higher clearance than adolescents or adults (see Special Populations below).

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, ine sulfate extended-rel ase capsules demonstrates linear pharmacokinetics over the dose anipite damine sunate exterior release capsules demonstrates linear pharmaconnects over the dose range of 20 to 60 mg in adults and adolescents weighing greater than 75 kg/165 lbs, over the dose range of 10 to 40 mg in adolescents weighing less than or equal to 75 kg/165 lbs, and 5 to 30 mg in children aged 6 to 12 years. There is no unexpected accumulation at steady state in children.

Food does not affect the extent of absorption of d-amphetamine and I-amphetamine, but prolongs Tmax by 2.5 hours (from 5.2 hrs at fasted state to 7.7 hrs after a high-fat meal) for d-ampletamine and 2.7 hours (from 5.6 hrs at fasted state to 8.3 hrs after a high-fat meal) for d-ampletamine after administration of dextroampletamine saccharate, ampletamine aspartate monohydrate, dextroampletamine sulfate ampletamine sulfate extended-release capsules 30 mg. Opening the capsule and sprinkling the contents on applesauce results in comparable absorption to the intact capsule taken in the fasted state. Equal dense of devtergemented release capsules 30 mg. Opening the capsule and sprinkling the contents on applesauce results in comparable absorption to the intact capsule taken in the fasted state. Equal doses of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamp sulfate, amphetamine sulfate extended-release capsules strengths are bioequivalent.

Metabolism and Excretion

Ampletamine is reported to be oxidized at the 4 position of the benzene ring to form 4-hydroxyamphetamine, or on the side chain α or β carbons to form alpha-hydroxy-amphetamine or norephedrine. respectively. Norephedrine and 4-hydroxy-amphetamine are both active and each is subsequently oxidized to form 4-hydroxy-norephedrine. Alpha-hydroxy-amphetamine undergoes deamination to form phenylacetone, which ultimately forms benzoic acid and its glucuronide and the glycine conjugate hippuric acid. Although the enzymes involved in amphetamine metabolism have not been clearly defined, CYP2Db is known to be Which ultimately forms behavior and any registration of the ground and the ground and the enzymes involved in ampletamine metabolism have not been clearly defined, CYP2D6 is known to be involved with formation of 4-hydroxy-ampletamine. Since CYP2D6 is genetically polymorphic, population variations in ampletamine metabolism are a possibility.

Amphetamine is known to inhibit monoamine oxidase, whereas the ability of amphetamine and its metabolites to inhibit various P450 isozymes and other enzymes has not been adequately elucidated. In vitro experiments with human microsomes indicate minor inhibition of CYP2D6 by amphetamine and minor inhibition of CYP1A2_206, and 3A4 by one or more metabolites. However, due to the probability of auto-inhibition and the lack of information on the concentration of these metabolites relative to *in vivo* concentrations, no predications regarding the potential for amphetamine or its metabolites to inhibit the metabolism of other drugs by CYP isozymes *in vivo* can be made.

metabolism of other drugs by CYP isozymes *in vivo* can be made. With normal urine pHs, approximately half of an administered dose of amphetamine is recoverable in urine as derivatives of alpha-hydroxy-amphetamine and approximately another 30 to 40% of the dose is recoverable in urine as amphetamine itself. Since amphetamine has a pKa of 9.9, urinary recovery of amphetamine is highly dependent on pH and urine flow rates. Alkaline urine pHs result in less ionization and reduced renal elimination, and acidic pHs and high flow rates result in increased renal elimination with clearances greater than glomerular filtration rates, indicating the involvement of active secretion. Urinary recovery of amphetamine has been reported to range from 1 to 75%, depending on urinary pH, with the remaining fraction of the dose hepatically metabolized. Consequently, both hepatic and renal dysfunction have the potential to inhibit the elimination of amphetamine, and any decrease in amphetamine's metabolism that might occur due to drug interactions or genetic polymorphisms is more likely to be clinically significant when renal elimination is decreased *[see Drug Interactions (7)]*. Special Pooulations

Special Populations

Comparison of the pharmacokinetics of d- and I-amphetamine after oral administration of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules in children (6 to 12 years) and adolescent (13 to 17 years) ADHD patients and healthy adult volunteers indicates that body weight is the primary determinant of apparent differences in the pharmacokinetics of d- and I-amphetamine across the age range. Systemic exposure measured by area under the curve to infinity (AUC), and maximum plasma concentration (Cma) decreased with increases in body weight, while oral volume of distribution (V₂/F), oral clearance (CL/F), and elimination half-life (t.,) increased with increases in body weight is porter with a processing the processing half-life (t1/2) increased with increases in body weight.

teacher-rated behavior and performance measures, compared to patients treated with placebo. A double-blind, randomized, multicenter, parallel-group, placebo-controlled study was conducted in adolescents aged 13 to 17 (N=327) who met DSM-N® criteria for ADHD. The primary cohort of patients (n=287, weighing \leq 75 kg/165 lbs) were randomized to tixed-dose treatment groups and received four weeks of treatment. Patients were randomized to texeive final doses of 10, 20, 30, and 40 mg dextroamphetamine suchatet, amphetamine aspartate monohydrate, dextroamphetamine, Patients trandomized to the doses of 10, 20, 30, and to doses yrater than 10 mg were titrated to their final doses by 10 mg each week. The secondary cohort consisted of 40 subjects weighing >75 kg/165 lbs who were randomized to fixed-dose treatment groups receiving final doses of 50 and 60 mg dextroamphetamine saccharate, amphetamine sulfate extended-release capsules or placebo once daily in the morning. Patients were the anothydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules or placebo once daily in the morning for 4 weeks. The primary efficacy variable was the Attention Deficit hyperactivity Disorder-Rating Scale IV (ADHD-RS-IV) total score for the primary cohort. The ADHD-RS-IV is an 18-item scale that measures the core symptoms of ADHD. Improvements in the primary cohort were statistically significantly greater in all four primary cohort devtroamphetamine sulfate extended-release capsules 10 mg, 20 mg, 30 mg, and 40 mg) compared with the placebo group. There was not adequate evidence that doses greater than 20 mg/day conferred additional benefit. Adult Patients teacher-rated behavior and performance measures, compared to patients treated with placebo

Adult Patients A double-blind, randomized, placebo-controlled, parallel-group study was conducted in adults (N=255) who met DSM-IV® criteria for ADHD. Patients were randomized to fixed-dose treatment groups receiving

final doses of 20, 40, or 60 mg of dextroamphetamine saccharate, amphetamine aspartate monohydrat lextroamphetamine sulfate, amphetamine sulfate extended-release capsules or placebo once daily i the morning for four weeks. Significant improvements, measured with the Attention Deficit Hyperactivity Disorder-Rating Scale (ADHD-RS), an 18-item scale that measures the core symptoms of ADHD, were observed at endpoint for all dextroamphetamine saccharate, amphetamine aspartate monohydrate dextroamphetamine sulfate, amphetamine sulfate extended-release capsules doses compared to patients who received placebo for all four weeks. There was not adequate evidence that doses greater than 20 mg day conferred additional benefit

16 HOW SUPPLIED/STORAGE AND HANDLING

- Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules are supplied as follows:
- 5 mg extended release capsules: Hard Gelatin Capsule Shell Size "3" Blue Opaque Cap and Clear transparent body, imprinted with "5 mg" on cap and "T" on body in black ink filled with light to dark beige colored spherical pellets.

NDC 31722-185-01 bottles of 100 capsules

10 mg extended release capsules: Hard Gelatin Capsule Shell Size "3" Blue Opaque Cap and Blue transparent body, imprinted with "10 mg" on cap and "T" on body in black ink filled with light to dark beige colored spherical pellets. NDC 31722-186-01 bottles of 100 capsules 15 mg extended release capsules: Hard Gelatin Capsule Shell Size "2" White Opaque Cap and Blue transparent body, imprinted with "15 mg" on cap and "T" on body in black ink filled with light to dark

- beige colored spherical pellets. NDC 31722-187-01 bottles of 100 capsules
- 20 mg extended release capsules: Hard Gelatin Capsule Shell Size "2" Orange Opaque Cap and Orange transparent body, imprinted with "20 mg" on cap and "T" on body in black ink filled with light to dark beige colored spherical pellets. NDC 31722-188-01 bottles of 100 capsules

25 mg extended release capsules: Hard Gelatin Capsule Shell Size "1" White Opaque Cap and Orange transparent body, imprinted with "25 mg" on cap and "T" on body in black ink filled with light to dark data the second s

beige colored spherical pellets. NDC 31722-189-01 bottles of 100 capsules

30 mg extended release capsules: Hard Gelatin Capsule Shell Size "1" Yellow Opaque Cap imprinted with "30 mg" and White Opaque body imprinted with "T" in black ink filled with light to dark beige colored

- NDC 31722-195-01 bottles of 100 capsules
- Dispense in a tight, light-resistant container as defined in the USP. Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Abuse, Misuse, and Addiction

Educate patients and their families about the risks of abuse, misuse, and addiction of dextroamphetar Educate patients and their families about the risks of abuse, misuse, and addiction of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules, which can lead to overdose and death, and proper disposal of any unused drug (see Warnings and Precautions (5.1), Drug Abuse and Dependence (9.2), Overdosage (10)]. Advise patients to store dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules in a safe place, preferably locked, and instruct patients to not give dextroamphetamine sulfate excharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate over a substance over the substance of a substance over the substanc

Risks to Patients with Serious Cardiac Disease

Advise patients that there are potential risks to patients with serious cardiac disease, including sudden death, with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules use. Instruct patients to contact a healthcare provider immediately if they develog symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease *(see Warnings and Precautions (5.2))*.

Increased Blood Pressure and Heart Rate

Advise patients that dextroamphetamine saccharate, amphetamine aspartate monohydrate dextroamphetamine sulfate, amphetamine sulfate extended-release capsules can cause elevations ir blood pressure and heart rate [see Warnings and Precautions (5.3)].

Psychiatric Adverse Reactions

Expendence Reactions Prior to initiating treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules, adequately screen patients with comorbid depressive symptoms to determine if they are at risk for bipolar disorder. Such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and/ or depression. Additionally, dextroamphetamine saccharate, amphetamine asparate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules therapy at usual doses may cause treatment-emergent psychotic or manic symptoms in patients without prior history of psychotic symptoms or mania [see Warnings and Precautions (5.4)].

Circulation Problems in Fingers and Toes [Peripheral Vasculopathy, Including Raynaud's Phenomenon] Instruct patients beginning treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules about the risk of peripheral vasculopathy, including Raynaud's Phenomenon, and in associated signs and toms: finders or toes may feel numb, cool, painful, and/or may change color from pale, to blue to red. Instruct patients to report to their obscipations any new numberss, pains, which are the second sec release capsules. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients Isee Warnings and Precautions (5.7)

Serotonin Syndrome

<u>Growth</u>

Sertionin syndrome Caution patients about the risk of serotonin syndrome with concomitant use of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules and other serotonergic drugs including SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspione, St. John's Wort, and with drugs that impair metabolism of serotonin (in particular MAOIs, both those intended to treat psychiatric disorders and also others such as linezolid) *(see Contraindications (4), Warnings and Precautions (5.8), Drug Interactions (7.1)*. Advise patients to contact their healthcare provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome.

Concomitant Medications Advise patients to notify their physicians if they are taking, or plan to take, any prescription or over-thecounter drugs because there is a potential for interactions [see Drug Interactions (7.1)]

MEDICATION GUIDE Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate,

amphetamine Sulfate. Amphetamine Sulfate Extended-Release Capsules CII

(dex'' troe am fet' a meen sak" a rate), (am fet' a meen a spar" tate mon" oh hye' drate), (dex'' troe am fet' a meen sul' fate), (am fet' a meen sul' fate) What is the most important information I should know about dextroamphetamine saccharate nphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfat xtended-release capsules?

extroamphetamine saccharate, amphetamine aspartate monohydrate, dextroam ulfate, amphetamine sulfate extended-release capsules may cause serious side effect

Abuse, misuse, and addiction. Dextroamphetamine saccharate, amphetamine asparta monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsule has a high chance for abuse and misuse and may lead to substance use problems, including addiction. Misuse and abuse of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules other amphetamine containing medicines, and methylphenidate containing medicines, ca d to overdose and death. The risk of overdose and death is increased with higher doses dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamin sulfate, amphetamine sulfate extended-release capsules or when it is used in ways that are no approved, such as snorting or injection.

- Your healthcare provider should check you or your child's risk for abuse, misuse, and addiction before starting treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules and will monitor you or your child during treatment.
- Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetam sulfate, amphetamine sulfate extended-release capsules may lead to physical dependence after prolonged use, even if taken as directed by your healthcare provider
- Do not give dextroamphetamine saccharate, amphetamine aspartate monohydrat dextroamphetamine sulfate, amphetamine sulfate extended-release capsules to anyone else See "What are dextroamphetamine saccharate, amphetamine aspartate monohydrate dextroamphetamine sulfate, amphetamine sulfate extended-release capsules?" fo more information.
- Keep dextroamphetamine saccharate, amphetamine aspartate monohydrat dextroamphetamine sulfate, amphetamine sulfate extended-release capsules in a safe place and properly dispose of any unused medicine. See "How should I store dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate amphetamine sulfate extended-release cansules?" for more information
- ell vour healthcare provider if vou or vour child have ever abused or been dependent on alcoho escription medicines, or street drugs.

Risks for people with serious heart disease. Sudden death has happened in people who ha heart defects or other serious heart disease

our healthcare provider should check you or your child carefully for heart problems befor tarting treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrat dextroamphetamine sulfate, amphetamine sulfate extended-release capsules. Tell your healthcar rovider if you or your child have any heart problems, heart disease, or heart defects.

Call your healthcare provider or go to the nearest hospital emergency room right away i you or your child have any signs of heart problems such as chest pain, shortness of breath or fainting during treatment with destroamphetemine caceborate such that is a sector of the s uo of your china nave any signs or near problems such as chiest pain, shortness or beard r fainting during treatment with dextroamphetamine saccharate, amphetamine aspartat ionohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsule: Increased blood pressure and heart rate.

Your healthcare provider should check you or your child's blood pressure and heart rate regular during treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate dextroamphetamine sulfate, amphetamine sulfate extended-release capsules. Mental (psychiatric) problems, including:

- new or worse behavior or thought problems
- new or worse bipolar illness
- new psychotic symptoms (such as hearing voices, or seeing or believing things that are no
- real) or new manic symptoms ell your healthcare provider about any mental problems you or your child have or about a fami
- istory of suicide, bipolar illness, or depression. Call your healthcare provider right away if you or your child have any new or worsening men

ymptoms or problems during treatment with dextroamphetamine saccharate, amphetamin spartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-releas apsules, especially hearing voices, seeing or believing things that are not real, or new anic symptoms.

What are dextroamphetamine saccharate, amphetamine aspartate monohydrate nine sulfate, amphetamine sulfate extended-release capsules

extroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate mphetamine sulfate extended-release capsules are central nervous system (CNS) stimular escription medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) i adults and children 6 years of age and older. Dextroamphetamine saccharate, amphetamine asparata monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules may help crease attention and decrease impulsiveness and hyperactivity in people with ADHD.

t is not known if dextroamphetamine saccharate, amphetamine aspartate monohydrate troamphetamine sulfate, amphetamine sulfate extended-release capsules is safe and effective n children under 6 years of age.

extroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamp ulfate, amphetamine sulfate extended-release capsules is a federally controlled substance CII) because it contains amphetamine that can be a target for people who abuse prescriptio nedicines or street drugs. Keep dextroamphetamine saccharate, amphetamine aspartat nonohydrate dextroamphetamine sulfate amphetamine sulfate extended-release cansules in aspartate monohydrate, dextroamphetamine suifate, amphetamine suifate extended release capsules in a safe place to protect it from theft. Never give your dextroamphetamine saccharate, amphetamina aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules anvone else because it may cause death or harm them. Selling or giving away dextroamphetamin accharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfat tended-release capsules may harm others and is against the law.

Do not take dextroamphetamine saccharate, amphetamine aspartate monohydrate dextroamphetamine sulfate, amphetamine sulfate extended-release capsules if you or you hild:

are taking or have taken within the past 14 days, a medicine used to treat depression called monoamine oxidase inhibitor (MAOI), including the antibiotic linezolid or the intravenous medicin methvlene blue

are allergic to amphetamine products or any of the ingredients in dextroamphetamine saccharate amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended release capsules. See the end of this Medication Guide for a complete list of ingredients in dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamin sulfate amphetamine sulfate extended-release cansules

How should dextroamphetamine saccharate, amphetamine aspartate monohydrate, ktroamphetamine sulfate, amphetamine sulfate extended-release capsules be taken? Take dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetami nine sulfate extended-release capsules exactly as prescribed by your or you

child's healthcare provider. Your healthcare provider may change the dose if needed. Manufactured by:

Manufactured for:

Piscataway, NJ 08854

Ascent Pharmaceuticals, Inc. Central Islip, NY 11722

Camber Pharmaceuticals, Inc.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Revised: 09/24

Take dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamin sulfate, amphetamine sulfate extended-release capsules 1 time each day in the morning whe you first wake up.

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetar sulfate, amphetamine sulfate extended-release capsules can be taken with or without food. Swallow dextroamphetamine saccharate, amphetamine aspartate monohydrate dextroamphetamine sulfate amphetamine sulfate extended-release capsules whole. If you o your child cannot swallow the capsule whole, open it and sprinkle the medicine on applesauce Swallow all of the applesauce and medicine mixture right away.

- **Do not** chew the applesauce and medicine mixture.
- Do not store the applesauce sprinkled with dextroamphetamine saccharate, amphetamin aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate exte capsules

you or your child take too much dextroamphetamine saccharate, amphetamine aspartat nohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules, cal our healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospita ergency room right away.

What are the possible side effects of dextroamphetamine saccharate, amphetamine aspartate nohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release cansules) Dextroamphetamine saccharate, amphetamine aspartate monohvdrate. dextroamnheta etamine sulfate extended-release capsules may cause serious side effect

See "What is the most important information I should know about dextroampheta saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate amphetamine sulfate extended-release capsules?"

Slowing of growth (height and weight) in children. Children should have their height and weight checked often during treatment with dextroamphetamine saccharate, amphetamine aspartat monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules Your healthcare provider may stop your child's dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules treatment if they are not growing or gaining weight as expected.

Seizures. Your healthcare provider may stop treatment with dextroamphetamine saccharate amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended release capsules if you or your child have a seizure.

Circulation problems in fingers and toes (peripheral vasculopathy, including Raynaud's

Signs and symptoms may include:

• agitation, hallucinations, coma, or

other changes in mental status

• problems controlling movements or

sulfate, amphetamine sulfate extended-release capsules

muscle twitching

loss of coordination

· loss of appetite

trouble sleeping

mood swings

loss of appetite

• dry mouth

headache

· weight loss

nausea

anxiety

loss of appetite

trouble sleeping

• trouble sleeping

stomach (abdominal) pain

in adolescents ages 13 to 17 include:

stomach (abdominal pain)

fast heartbeat

o seizures

• fingers or toes may feel numb, cool, painful

• fingers or toes may change color from pale, to blue, to red Tell your healthcare provider if you have or your child have any numbness, pain, skin color change

or sensitivity to temperature in your fingers or toes. Call your healthcare provider right away if you have or your child have any signs of

unexplained wounds appearing on fingers or toes during treatment with dextroamphetamis saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfa amphetamine sulfate extended-release capsules.

Serotonin syndrome. This problem may happen when dextroamphetamine saccharate release capsules is taken with certain other medicines and may be life-threatening. Stop takin dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamin sulfate, amphetamine sulfate extended-release capsules and call your healthcare provider of go to the nearest hospital emergency room right away if you or your child develop any of th following signs and symptoms of serotonin syndrome

New or worsening tics or worsening Tourette's Syndrome. Tell your healthcare provider if you

or your child get any new or worsening tics or worsening Tourette's syndrome during treatment

with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetami

he most common side effects of dextroamphetamine saccharate, amphetamine aspartat

vomiting

nervousness

weight loss

nervousness

nausea

fever

The most common side effects of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules

The most common side effects of dextroamphetamine saccharate, amphetamine aspartate nonohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules n adults include:

agitation

fast heartbeat

urinary tract infections (UTIs)

dizziness

diarrhea

weakness

nese are not all the possible side effects of dextroamphetamine saccharate, amphetamine aspartat

nonohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules.

monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsu in children ages 6 to 12 include:

confusion

dizziness

change in blood pressure

 nausea, vomiting, or diarrhea muscle stiffness or tightness

high body temperature (hyperthermia)

sweating or fever

Pediatric Patients	Monitor growth in children during treatment with dextroamphetamine saccharate, amphetamine	Before taking dextroamphetamine saccharate, amphetamine aspartate monohydrate,	monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules.
On a mg/kg weight basis, children eliminated amphetamine faster than adults. The elimination half-	aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules,	dextroamphetamine sulfate, amphetamine sulfate extended-release capsules tell your	Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800- FDA-1088.
life ($t_{1/2}$) is approximately 1 hour shorter for d-amphetamine and 2 hours shorter for I-amphetamine in children than in adults. However, children had higher systemic exposure to amphetamine (C_{max} and AUC)		healthcare provider about all of your or your child's medical conditions, including if you or your child:	How should I store dextroamphetamine saccharate, amphetamine aspartate monohydrate,
than adults for a given dose of dextroamphetamine saccharate, amphetamine aspartate monohydrate,	Motor and Verbal Tics, and Worsening of Tourette's Syndrome		dextroamphetamine sulfate, amphetamine sulfate extended-release capsules
dextroamphetamine sulfate, amphetamine sulfate extended-release capsules, which was attributed to		have heart problems, heart disease, heart defects, or high blood pressure	Store dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine
the higher dose administered to children on a mg/kg body weight basis compared to adults. Upon dose normalization on a mg/kg basis, children showed 30% less systemic exposure compared to adults.	with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules. Instruct patients to notify their healthcare provider if	 have mental problems including psychosis, mania, bipolar illness, or depression, or have a family history of suicide, bipolar illness, or depression 	sulfate, ampletamine sulfate extended-release capsules at room temperature between 68 to 77°F (20 to 25°C).
Gender Systemic exposure to amphetamine was 20 to 30% higher in women (N=20) than in men (N=20) due to	emergence of new tics or worsening of tics or Tourette's syndrome occurs [see Warnings and Precautions (5.9)].	have kidney problems	 Protect dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine
Systemic exposure to ampletatimite was 20 to 30% infinite in women ($w=20$) that in time ($w=20$) due to the higher dose administered to women on a mg/kg body weight basis. When the exposure parameters (C_{max} and AUC) were normalized by dose (mg/kg), these differences diminished. Age and gender had no	Pregnancy Registry	 have seizures or have had an abnormal brain wave test (EEG) have circulation problems in fingers and toes 	sulfate, amphetamine sulfate extended-release capsules from light.
direct effect on the pharmacokinetics of d- and l-amphetamine.	Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women	3	 Store dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules in a safe place, like a locked cabinet.
Race	exposed to dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules during pregnancy [see Use in Specific	 have or had repeated movements or sounds (tics) or Tourette's syndrome, or have a family history of tics or Tourette's syndrome 	 Dispose of remaining, unused, or expired dextroamphetamine saccharate, amphetamine aspartate
Formal pharmacokinetic studies for race have not been conducted. However, amphetamine	Populations (8.1)].		monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules by a
pharmacokinetics appeared to be comparable among Caucasians (N=33), Blacks (N=8), and Hispanics	Pregnancy	 are pregnant or plan to become pregnant. It is not known if dextroamphetamine saccharate, amphetamine aspartate monohydrate. dextroamphetamine sulfate. amphetamine sulfate extended- 	medicine take-back program at a U.S. Drug Enforcement Administration (DEA) authorized collection
(N=10).	Advise patients to notify their healthcare provider if they become pregnant or intend to become	release capsules will harm the unborn baby. Tell your healthcare provider if you or your child	site. If no take-back program or DEA authorized collector is available, mix dextroamphetamine
Patients with Renal Impairment	pregnant during treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate,	become pregnant during treatment with dextroamphetamine saccharate, amphetamine aspartate	saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine
The effect of renal impairment on d- and l-amphetamine after administration of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate	dextroamphetamine sulfate, amphetamine sulfate extended-release capsules. Advise patients of the potential fetal effects from the use of dextroamphetamine saccharate, amphetamine aspartate	monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules.	sulfate extended-release capsules with an undesirable, nontoxic substance such as dirt, cat litter, or
extended-release capsules has not been studied. The impact of renal impairment on the disposition	monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules during	• There is a pregnancy registry for females who are exposed to dextroamphetamine saccharate.	used coffee grounds to make it less appealing to children and pets. Place the mixture in a container
of amphetamine is expected to be similar between oral administration of lisdexamfetamine and	pregnancy [see Use in Specific Populations (8.1)].	amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate	such as a sealed plastic bag and throw away dextroamphetamine saccharate, amphetamine
dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules.	Lactation	extended-release capsules during pregnancy. The purpose of the registry is to collect	aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules in the household trash. Visit www.fda.gov/drugdisposal for additional information on
In a pharmacokinetic study of lisdexamfetamine in adult subjects with normal and impaired renal function.	Advise women not to breastfeed if they are taking dextroamphetamine saccharate, amphetamine aspartate	information about the health of females exposed to dextroamphetamine saccharate,	disposal of unused medicines.
mean d-amphetamine clearance was reduced from 0.7 L/hr/kg in normal subjects to 0.4 L/hr/kg in	monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules [see Use in Specific Populations (8.2)].	amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate	Keep dextroamphetamine saccharate, amphetamine aspartate monohydrate,
subjects with severe renal impairment (GFR 15 to <30mL/min/1.73 m ²). Dialysis did not significantly	For more information call Camber Pharmaceuticals. Inc., at 1-866-495-8330.	extended-release capsules and their baby. If you or your child becomes pregnant during	dextroamphetamine sulfate, amphetamine sulfate extended-release capsules and all medicines
affect the clearance of d-amphetamine [see Use in Specific Populations (8.6)].	Manufactured by:	treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules, talk to your	out of the reach of children.
13 NONCLINICAL TOXICOLOGY	Ascent Pharmaceuticals. Inc.	healthcare provider about registering with the National Pregnancy Registry of Psychostimulants	
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility	Central Islip, NY 11722	at 1-866-961-2388 or visit online at https://womensmentalhealth.org/clinical-and-research-	General information about the safe and effective use of dextroamphetamine saccharate,
Carcinogenesis	Name of the second form	programs/pregnancyregistry/othermedications/.	amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules.
No evidence of carcinogenicity was found in studies in which d,I-amphetamine (enantiomer ratio of 1:1)	Manufactured for: Camber Pharmaceuticals. Inc.	are breastfeeding or plan to breastfeed. Dextroamphetamine saccharate, amphetamine aspartate	
was administered to mice and rats in the diet for 2 years at doses of up to 30 mg/kg/day in male mice, 19 mg/kg/day in female mice, and 5 mg/kg/day in male and female rats. These doses are approximately	Piscataway, NJ 08854	monohydrate, dextroamphetamine sulfate, amphetamine sulfate passes into breast milk. You	Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine
2.4, 1.5, and 0.8 times, respectively, the maximum recommended human dose of 30 mg/day given to		or your child should not breastfeed during treatment with dextroamphetamine saccharate,	sulfate, amphetamine sulfate extended-release capsules for a condition for which it was not
children, on a mg/m ² basis.	Rev: 09/24	amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate	prescribed. Do not give dextroamphetamine saccharate, amphetamine aspartate monohydrate.
Mutagenesis		extended-release capsules. Talk to your healthcare provider about the best way to feed the baby	dextroamphetamine sulfate, amphetamine sulfate extended-release capsules to other people, even
Amphetamine, in the enantiomer ratio d- to I- ratio of 3:1, was not clastogenic in the mouse bone marrow		during treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules.	if they have the same condition. It may harm them and it is against the law.
micronucleus test <i>in vivo</i> and was negative when tested in the <i>E. coli</i> component of the Ames test <i>in vitro</i> . d, I-Amphetamine (1:1 enantiomer ratio) has been reported to produce a positive response in the mouse			You can ask your healthcare provider or pharmacist for information about dextroamphetamine
bone marrow micronucleus test, an equivocal response in the Ames test, and negative responses in the in		Tell your healthcare provider about all of the medicines that you or your child take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.	saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules that is written for healthcare professionals.
vitro sister chromatid exchange and chromosomal aberration assays.		Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate,	extended-release capsules that is written for realincare professionals.
Impairment of Fertility		amphetamine sulfate extended-release capsules and some medicines may interact with each other	What are the ingredients in dextroamphetamine saccharate, amphetamine aspartate monohydrate,
Amphetamine, in the enantiomer ratio d- to I- ratio of 3:1, did not adversely affect fertility or early embryonic development in the rat at doses of up to 20 mg/kg/day (approximately 8 times the maximum		and cause serious side effects. Sometimes the doses of other medicines will need to be changed	dextroamphetamine sulfate and amphetamine sulfate extended-release capsules?
recommended human dose of 20 mg/day given to adolescents, on a mg/m ² basis).		during treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate,	Active Ingredients: Amphetamine aspartate monohydrate, amphetamine sulfate, dextroamphetamine
13.2 Animal Toxicology and/or Pharmacology		dextroamphetamine sulfate, amphetamine sulfate extended-release capsules.	sulfate and dextroamphetamine saccharate.
Acute administration of high doses of amphetamine (d- or d, I-) has been shown to produce long-lasting		Your healthcare provider will decide if dextroamphetamine saccharate, amphetamine aspartate	Inactive Ingredients: The inactive ingredients in dextroamphetamine saccharate, amphetamine
neurotoxic effects, including irreversible nerve fiber damage in rodents. The significance of these findings		monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules can	aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules include: Sugar spheres, hydroxy propyl methyl cellulose, talc, triethyl citrate, methacrylic
to humans is unknown.		be taken with other medicines.	acid-ethyl acrylate copolymer, hard gelatin capsules, titanium dioxide, polyethylene glycol, iron oxide
14 CLINICAL STUDIES		Especially tell your healthcare provider if you or your child take:	yellow, polysorbate 80, iron oxide red. The 5 mg capsule shell contain Titanium dioxide, FD & C Blue 1,
Pediatric Patients		· · · · · · · · · · · · · · · · · · ·	FD & C Red 40, gelatin and sodium lauryl sulfate. The 10 mg capsule shell contain Titanium dioxide,
A double-blind, randomized, placebo-controlled, parallel-group study was conducted in children aged 6 to		selective serotonin reuptake inhibitors (SSRIs) serotonin norepinephrine	FD & C Blue 1, FD & C Red 40, gelatin, sodium lauryl sulfate and D&C Red 28. The 15 mg capsule
12 (N=584) who met DSM-IV [®] criteria for ADHD (either the combined type or the hyperactive-impulsive type). Patients were randomized to fixed-dose treatment groups receiving final doses of 10, 20, or 30 mg		medicines used to treat migraine headaches called reuptake inhibitors (SNRIs)	shell contain Titanium dioxide, FD & C Blue 1, D & C Red 28, gelatin and sodium lauryl sulfate. The
of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate,		triptans • tricyclic antidepressants	20 mg capsule shell contain Titanium dioxide, FD & C Red 3, FD & C Yellow 6, FD & C Blue 1, gelatin,
amphetamine sulfate extended-release capsules or placebo once daily in the morning for three weeks.		Ithium fentanyl	sodium lauryl sulfate and FD & C Red 40. The 25 mg capsule shell contain Titanium dioxide, FD & C Red 40, FD & C Yellow 6, gelatin, sodium lauryl sulfate. The 30 mg capsule shell contain Titanium
Significant improvements in patient behavior, based upon teacher ratings of attention and hyperactivity, were observed for all dextroamphetamine saccharate, amphetamine aspartate monohydrate,		tramadol tryptophan St. Jaba's Wort	dioxide, FD & C Yellow 6, D & C Yellow 10, sodium lauryl sulfate and gelatin. The ink ingredients
dextroamphetamine sulfate, amphetamine sulfate extended-release capsules doses compared to		buspirone St. John's Wort	common for all strengths are shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene
patients who received placebo, for all three weeks, including the first week of treatment, when all		Know the medicines that you or your child take. Keep a list of your or your child's medicines with	glycol, strong ammonia solution, black iron oxide, potassium hydroxide.
dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules subjects were receiving a dose of 10 mg/day. Patients		you to show your healthcare provider and pharmacist when you or your child get a new medicine.	For more information, you may also contact Camber Pharmaceuticals, Inc., at 1-866-495-8330.
who received dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine		Do not start any new medicine during treatment with dextroamphetamine saccharate,	Medication Guide available at http://camberpharma.com/medication-guides
sulfate, amphetamine sulfate extended-release capsules showed behavioral improvements in both		amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate	monoulon dura aranasis at <u>http://damborpharma.com/modioation-guides</u>
morning and afternoon assessments compared to patients on placebo.		extended-release capsules without talking to your healthcare provider first.	
In a classroom analogue study, patients (N=51) receiving fixed doses of 10, 20, or 30 mg dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate,			
amphetamine sulfate extended-release capsules demonstrated statistically significant improvements in			